Tesamorelin to reduce liver fat in adults with fatty liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double‑blind, placebo‑controlled Phase II study in which adults with elevated liver fat are assigned 1:1 to daily subcutaneous tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling for all participants. Liver fat is measured by MRI‑proton density fat fraction (MRI‑PDFF) at baseline, week 24, and week 52, and the primary endpoint is change in MRI‑PDFF from baseline to week 52. Key secondary outcomes include the proportion achieving a ≥30% relative decline in MRI‑PDFF, changes in liver enzymes and noninvasive fibrosis measures, and metabolic markers such as glucose, HbA1c, HOMA‑IR, and lipids. Safety monitoring emphasizes glucose metrics and IGF‑1 with dose adjustment rules to handle elevated IGF‑1 while preserving blinding.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults age 18 to 75 years, able to provide informed consent.
* Evidence of hepatic steatosis consistent with MASLD/NAFLD, defined as MRI-PDFF \>=10% at screening (or equivalent imaging documentation if MRI-PDFF was performed within the prior 8 weeks).
* Fibrosis risk compatible with non-cirrhotic disease (e.g., FibroScan liver stiffness below a prespecified threshold and no clinical evidence of portal hypertension).
* Stable body weight (+/-5%) for at least 3 months prior to screening.
* If on diabetes, lipid-lowering, antihypertensive, or weight-loss medications, regimen is stable for at least 3 months prior to screening and expected to remain stable through week 52.
* Willingness and ability to self-administer daily subcutaneous injections (or have a trained caregiver).
* For participants of childbearing potential: agreement to use reliable contraception during treatment and for 30 days after the last dose; negative pregnancy test at screening and baseline.

Exclusion Criteria:

* Significant alcohol consumption consistent with alcohol-associated liver disease (e.g., \>20 g/day for women or \>30 g/day for men for sustained periods).
* Other chronic liver diseases (e.g., chronic hepatitis B, chronic hepatitis C with viremia, autoimmune hepatitis, Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency).
* Known cirrhosis or decompensated liver disease; or biopsy-proven stage 4 fibrosis if baseline biopsy is performed.
* Poorly controlled diabetes or conditions increasing ocular risk (e.g., HbA1c at or above a protocol threshold; active/untreated diabetic retinopathy).
* Use of exogenous growth hormone or GHRH analogs within the past 12 months.
* Chronic systemic corticosteroids or chronic use of medications known to induce or worsen steatosis or liver injury (e.g., amiodarone, tamoxifen, methotrexate).
* Active malignancy or high risk for recurrence judged unsafe by investigators.
* Contraindications to MRI (e.g., certain implanted devices) if MRI-PDFF is required.
* Pregnancy or breastfeeding.
* Known hypersensitivity to tesamorelin or formulation excipients (e.g., mannitol).
* Bariatric surgery within the last 12 months, or planned bariatric surgery during the study period.

Where it's running

• Peking University Shenzhen Hospital
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Study coordinator: Seni S Lu, Phd
• Email: Seni-Lu@beijing-biotech.com
• Phone: +86 13076790030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-hepatectomy rehabilitation with mazdutide for obese MASLD donors

  This trial tests whether adding mazdutide to a structured lifestyle plan helps overweight MASLD donors lose liver fat faster to become eligible for donation.

  Recruiting Phase 4 West China Hospital · Hefei, Anhui and 3 other locations · NCT07718126

• Photon-counting CT and ultrasound for detecting liver fat and scarring

  This will test whether a new photon-counting CT plus ultrasound can find liver fat and scarring in adults with fatty liver or liver fibrosis, using MRI as the reference.

  Recruiting Duke University · Durham, North Carolina · NCT07495332

• Non-invasive blood and imaging tests for metabolic liver disease

  This project tests whether blood tests and imaging scans can diagnose and stage metabolic-associated steatohepatitis (MASH) and liver fibrosis in adults with metabolic risk factors.

  Recruiting at 4 sites Foundation for the National Institutes of Health · Miami, Florida and 3 other locations · NCT07122700

• Effects of exercise on liver glucose production in Type 2 diabetes and fatty liver

  This study tests how exercise affects liver sugar production in people with Type 2 diabetes and fatty liver compared to healthy individuals.

  Recruiting AdventHealth Translational Research Institute · Orlando, Florida · NCT06993454

• New medication for treating liver diseases

  This study is testing a new medication for people with liver diseases to see if it is safe and helps reduce liver fat and inflammation.

  Recruiting Phase 1 Novo Nordisk A/S · Harrow · NCT06891365

• Investigating body fat distribution and its impact on metabolic diseases in Japanese adults

  This study looks at how the way body fat is distributed affects the risk of metabolic and heart diseases in Japanese adults.

  Recruiting Osaka Metropolitan University · Sakai, Osaka · NCT06694012

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.